Two early studies published in Nature July 5 showed promise for individualized cancer vaccines based on patient-specific tumor mutations, further reviving optimism for therapeutic cancer vaccines, a field of research that has generated excitement and disappointment over the years.
BioNTech, Neon Take A Step Forward In Personalized Cancer Vaccines
Two studies published in Nature July 5 showed that personalized cancer vaccines from BioNTech and Neon Therapeutics delivered potent immune responses in patients with melanoma. Both companies are moving forward with new studies.
